Varenicline for Smoking Reduction in Veterans Not Ready To Quit

Conditions

• Cigarette Smoking
• Tobacco Dependence
• Tobacco Use Disorder
• Veterans

Eligibility Criteria

Sex

ALL

Age

21 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Motivation-Phase Varenicline — DRUG
  Varenicline reduction dosing will start when participants initiate Motivation-phase treatment: 0.5mg once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the duration of the 12-week reduction regimen.
• Motivation-Phase Nicotine Mini-Lozenge — DRUG
  NRT mini-lozenge reduction dosing will start when participants initiate Motivation-phase treatment: 2-mg mini-lozenges in place of cigarettes (5-15/day).
• Cessation-Phase Combination Nicotine Replacement Therapy (NRT) — DRUG
  Combination NRT (nicotine patch + nicotine mini-lozenge) cessation dosing will begin on the target quit day: if smoking \>10 cigarettes/day = 8 weeks of 21-mg, 2 weeks of 14-mg, and 2 weeks of 7-mg nicotine patches; if smoking 10 cigarettes/day = 10 weeks of 14-mg and 2 weeks of 7-mg nicotine patches. All participants will receive 2 or 4 mg mini-lozenge for the 12-week cessation period (9/day, 1 piece every 1-2/hours).
• Cessation-Phase Varenicline — DRUG
  Varenicline cessation dosing will start one week prior to their TQD: 0.5mg once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the remainder of the 12-week cessation regimen.
• Motivation-Phase Counseling — BEHAVIORAL
  All participants receive motivation-phase counseling. Motivation-phase counseling involves 5, 10-15-minute counseling calls. The counselor will work with participants on smoking control skills selected by the participant, such as avoidance of smoking cues, reducing smoking heaviness/contexts, developing urge coping skills, or finding support from friends and family. Counseling will emphasize setting realistic and achievable smoking control goals. Counseling will also emphasize competence and self-efficacy, which will be linked to success in smoking control.
• Cessation-Phase Counseling — BEHAVIORAL
  All participants who enter cessation treatment will be offered 4, 10-15-minute counseling calls. The first counseling session involves pre-quit preparation, and can occur any time before the target quit day. The other 3 counseling calls will be scheduled for 1 day, 1 week, and 4 weeks after the target quit date. Cessation counseling will be based on treatment guidelines and will review instructions for when to start cessation medication, the timing of the quit day (relative to medication start), and medication adherence. Counseling will involve problem solving and skill development.

Study Details

In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.

Key Dates

Start date

Jul 1, 2026

Status verified

Apr 2026

Primary completion

Jun 28, 2030

Completion

Jun 28, 2030

Study Design

Enrollment

400 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Motivation-Phase Varenicline
  Varenicline use during pre-quit phase of smoking treatment for participants who are interested in cutting down on their smoking.
• Active Comparator: Motivation-Phase Nicotine Mini-Lozenge
  NRT mini-lozenge use during pre-quit phase of smoking treatment for participants who are interested in cutting down on their smoking.

Primary Outcome Measure

Biochemically confirmed 7-day point-prevalence abstinence [ Time Frame: 12 months post-study entry ]

Central Contacts

• Jessica M Cook, PhD
  (608) 256-1901
  [email protected]
• Elana G Brubaker, MSW BS
  (608) 256-1901
  [email protected]

Locations (4)

Find similar trials in San Diego, CA

Related Studies

• Free Samples for Health
  PHASE2 · Enrolling By Invitation · Hennepin Healthcare Research Institute · Minneapolis, Minnesota
• Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
  PHASE2 · Recruiting · VA Office of Research and Development · Durham, North Carolina
• Smoke-free Home Study in Subsidized Housing
  Recruiting · University of California, San Francisco · San Francisco, California
• Cannabidiol for Reducing Cigarette Use
  PHASE2 · Recruiting · University of California, Los Angeles · North Hollywood, California